As you were!
I looked up Hepatic Steatosis, which I had never heard of before, and see it is the technical term for 'fatty liver disease', which has been well-covered on this forum.
New to me, though, that EMV is funding the UQ research on this in 2021-22.
Perhaps the outcomes of the research will be available in the 2nd half of 2022. Something to look forward to while waiting for the outcomes of the brain scanner pivotal trials.
EMvision Research Notes, page-1240
-
- There are more pages in this discussion • 1,442 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.14 |
Change
0.120(5.94%) |
Mkt cap ! $183.0M | |||
| Open | High | Low | Value | Volume |
| $2.05 | $2.14 | $2.05 | $80.72K | 39.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $2.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.15 | 14500 | 2 |
View Market Depth
| Last trade - 15.57pm 13/09/2024 (20 minute delay) ? |
| EMV (ASX) Chart |